Bulletin
Investor Alert

Cyclerion Therapeutics Inc.

NAS: CYCN

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Jan 27, 2023, 4:41 p.m.

/zigman2/quotes/207301221/composite

$

0.67

Change

0.00 0.00%

Volume

Volume 100

Quotes are delayed by 20 min

/zigman2/quotes/207301221/composite

Previous close

$ 0.69

$ 0.67

Change

-0.02 -2.71%

Day low

Day high

$0.66

$0.72

Open

52 week low

52 week high

$0.35

$1.49

Open

Company Description

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for serious and orphan diseases, through the use of soluble guanylate cyclase (sGC) pharmacology. Its product pipeline includes several sGC sti...

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for serious and orphan diseases, through the use of soluble guanylate cyclase (sGC) pharmacology. Its product pipeline includes several sGC stimulators, a small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate (cGMP). The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.

Valuation

Price to Sales Ratio

17.08

Price to Book Ratio

1.55

Enterprise Value to EBITDA

0.53

Enterprise Value to Sales

-15.44

Efficiency

Total Asset Turnover

0.05

Liquidity

Current Ratio

5.00

Quick Ratio

5.00

Cash Ratio

4.87

Profitability

Gross Margin

88.03

Operating Margin

-1,159.67

Pretax Margin

-1,310.17

Net Margin

-1,310.17

Return on Assets

-59.12

Return on Equity

-95.87

Return on Total Capital

-59.57

Capital Structure

Officers and Executives

Name Age Officer Since Title
Dr. Peter M. Hecht 57 2019 Chief Executive Officer & Director
Ms. Cheryl Gault 41 - Head-Strategy
Ms. Anjeza Gjino 37 2019 Secretary & Vice President-Finance
Mr. Kevin Durfee - - Vice President-Information Technology & Facilities
Dr. G. Todd Milne - - Vice President-Corporate Development

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
06/03/2021 Peter M. Hecht
Chief Executive Officer; Director
823,170   Acquisition at $3.28 per share. 2,699,997
06/03/2021 Polaris Growth Management LLC
Director
3,322   Acquisition at $3.12 per share. 10,364
06/03/2021 Polaris Growth Management LLC
Director
92,831   Acquisition at $3.12 per share. 289,632
06/03/2021 Slate Path Capital LP
961,538   Acquisition at $3.12 per share. 2,999,998
05/06/2021 Peter M. Hecht
Chief Executive Officer; Director
302,000   Acquisition at $2.43 per share. 733,860
05/05/2021 Peter M. Hecht
Chief Executive Officer; Director
398,001   Acquisition at $2.53 per share. 1,006,942
05/04/2021 Peter M. Hecht
Chief Executive Officer; Director
300,000   Acquisition at $2.29 per share. 687,000
02/25/2021 Anjeza Gjino
Chief Financial Officer
1,824   Disposition at $4 per share. 7,296
02/25/2021 Christopher I. Wright
Chief Medical Officer
2,637   Disposition at $3.99 per share. 10,521
12/28/2020 Mark G. Currie
President and CSO
20,107   Disposition at $3.01 per share. 60,522
11/09/2020 Andreas Eugen Busch
Chief Innovation Officer
125,000   Acquisition at $2.53 per share. 316,250
11/06/2020 William I. Huyett
Chief Financial Officer
3,827   Disposition at $2.52 per share. 9,644
02/21/2020 William I. Huyett
Chief Financial Officer
3,559   Disposition at $5.12 per share. 18,222
12/30/2019 Mark G. Currie
President and CSO
25,000   Disposition at $2.48 per share. 62,000
/news/latest/company/us/cycn

MarketWatch News on CYCN

  1. Cyclerion Therapeutics started at buy with $14 stock price target at Truist

    6:45 a.m. Oct. 20, 2021

    - Tomi Kilgore

/news/nonmarketwatch/company/us/cycn

Other News on CYCN

  1. 10-Q: CYCLERION THERAPEUTICS, INC.

    4:13 p.m. Nov. 3, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  2. Cyclerion Therapeutics reports Q1 results

    4:40 p.m. May 4, 2022

    - Seeking Alpha

  3. 10-K: CYCLERION THERAPEUTICS, INC.

    4:10 p.m. Feb. 24, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  4. Warning: CYCN is at high risk of performing badly

    4:47 a.m. Nov. 12, 2021

    - Seeking Alpha

  5. Warning: CYCN is at high risk of performing badly

    3:38 a.m. Oct. 22, 2021

    - Seeking Alpha

  6. ME, CYCN and FWBI among pre market gainers

    7:28 a.m. Oct. 20, 2021

    - Seeking Alpha

  7. DPW, ANVS and CFMS among pre market gainers

    7:30 a.m. July 23, 2021

    - Seeking Alpha

  8. Loading more headlines...

At a Glance

Cyclerion Therapeutics, Inc.

Riverview II

245 First Street

18th floor

Cambridge, Massachusetts 02142

Phone

1 8573278778

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

Revenue

$3.94M

Net Income

$-51.65M

Employees

32.00

/news/pressrelease/company/us/cycn

Press Releases on CYCN

  1. Cyclerion Gains on Study Results

    8:57 a.m. June 17, 2022

    - Baystreet.ca

Link to MarketWatch's Slice.